AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021
Aug 10, 2021
29977_dirs_2021-08-10_ded6e6c3-9474-4cc4-a422-8054c8c4c4b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-06
Reporting Person: SCHLEIFER LEONARD S (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-06 | Common Stock | M | 240000 | $52.03 | Acquired | 573321 | Direct |
| 2021-08-06 | Common Stock | F | 137145 | $607.51 | Disposed | 436176 | Direct |
| 2021-08-06 | Common Stock | M | 160000 | $52.03 | Acquired | 596176 | Direct |
| 2021-08-06 | Common Stock | F | 91430 | $607.51 | Disposed | 504746 | Direct |
| 2021-05-19 | Common Stock | G | 41178 | $0.0 | Acquired | 41178 | Indirect |
| 2021-05-19 | Common Stock | G | 41178 | $0.0 | Disposed | 0 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-06 | Non-Qualified Stock Option (right to buy) | $52.03 | M | 240000 | Disposed | 2021-12-16 | Common Stock (240000) | Direct |
| 2021-08-06 | Non-Qualified Stock Option (right to buy) | $52.03 | M | 160000 | Disposed | 2021-12-16 | Common Stock (160000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 200000 | Indirect |
| Common Stock | 5874 | Indirect |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.
F3: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.